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Abstract
Background: The relative contribution of visceral (VAT) and subcutaneous (SAT) adipose tissue to cardiometabolic
disease is controversial. The aim of this study was to evaluate whether dissecting abdominal fat in VAT and SAT
using US may detect stronger and more specific association with MS, MS components, hyperuricemia and altered
liver enzymes compared to waist circumference.
Methods: We performed a cross-sectional study on 2414 subjects aged 18 to 66 years (71 % women) followed at
the International Center for the Assessment of Nutritional Status (ICANS, Milan, Italy). VAT and SAT were measured
using ultrasonography. Multivariable logistic regression controlling for age and gender was used to evaluate
the association of the parameters of interest (waist circumference (WC), VAT, SAT and VAT + SAT) with the MS
(international harmonized definition), its components (high triglycerides, low HDL, high blood pressure, high glucose),
high uric acid (≥7 mg/dl), high alanine transaminase (ALT, ≥ 30 U/l) and high gamma-glutamyl-transferase
(GGT, ≥ 30 U/l).
Results: VAT was independently associated with all the outcomes of interest, while SAT was independently
associated with MS and only with high blood pressure and high ALT when we considered the single parameters of MS
and NAFLD. VAT had the strongest association with high triglycerides, high ALT and high GGT. The VAT + SAT
association had the strongest association with MS. WC had the strongest association with low HDL and high
blood pressure. VAT and WC were similarly associated to high glucose and high uric acid.
Conclusion: US-determined VAT and SAT are both independently associated with MS. Moreover, to our knowledge,
we are the first to show that VAT, being associated to all of the MS components in addition to hyperuricemia and
altered liver enzymes, performs equally or better than WC except for high blood pressure and low HDL.
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Background
Abdominal fat distribution has been recognized as an
important risk factor for cardiometabolic disease (CMD)
[1]. Increased levels of abdominal visceral adipose tissue
(VAT) are associated with the metabolic syndrome (MS),
type 2 diabetes mellitus (T2DM), cardiovascular disease
[2–6], non-alcoholic fatty liver disease (NAFLD) [7, 8]
and hyperuricemia [9]. On the other hand, the contribu-
tion of subcutaneous adipose tissue (SAT) to CMD is
still debated [10].
Waist circumference (WC) is often used as surrogate
measure of abdominal fat, but it cannot separate the
effect of VAT from that of SAT [11]. Computed tomog-
raphy (CT) and magnetic resonance imaging (MRI) are
the reference methods for the assessment of VAT and
SAT [12, 13] and CT-measured VAT is associated with
MS more strongly than WC [2]. However, because they
are expensive and because CT exposes to ionizing radi-
ation, MRI and CT cannot be used in large epidemio-
logical studies. Ultrasonography (US) offers a cheap and
non-invasive alternative to MRI and CT [14–18]. US has
been used to measure abdominal VAT and SAT since the
early 90s and offers accurate and reproducible estimates
provided that standardized measurement protocols are
used [12–19].
US-determined VAT is associated with insulin resist-
ance, several CMD and NAFLD risk factors (e.g., fasting
glucose, lipid profile, blood pressure and liver enzymes)
[20–27]. However, the contribution of SAT to these out-
comes is controversial [20, 25–27]. It is also not clear
whether US-measured VAT and SAT are associated more
strongly with MS and its components, altered liver en-
zymes and hyperuciremia than is WC.
Therefore, the aim of the present cross-sectional study,
performed in a large sample of outpatients followed at a
Nutritional Research Center was to evaluate whether
dissecting abdominal fat in VAT and SAT using US may
detect stronger and more specific association with MS,
MS components, hyperuricemia and altered liver en-
zymes compared to waist circumference.
Methods
Subjects
2414 Caucasian subjects (1714 women, 71 %) were
consecutively studied at the International Center for the
Assessment of Nutritional Status (ICANS, Milan, Italy)
between September 2010 and June 2012. All subjects were
enrolled because of their interest to undergo a structured
nutritional assessment. Inclusion criteria were: 1) age ≥
18 years; 2) body mass index (BMI) ≥ 18.5 kg/m2. Exclu-
sion criteria were: 1) acute disease, e.g., influenza; 2) heart,
pulmonary, gastrointestinal, neurological or neoplastic
disease; 3) use of medications known to cause lipodystro-
phy, e.g., steroids and antiretroviral agents); 4) presence of
scars in the measurement area of VAT and SAT. On the
same morning, the subjects underwent a medical inter-
view, an anthropometric assessment, a measurement of
blood pressure, an abdominal US, and blood sampling.
The study was performed in accordance with the Declar-
ation of Helsinki and the subjects gave their written in-
formed consent. The local Ethical Committee approved
the study procedures.
Clinical and anthropometric assessment
A detailed medical interview was performed and the use
of any drug was recorded. Weight and height were mea-
sured following international guidelines [28]. BMI was
calculated as weight (kg) / height (m)2 and obesity was
classified following the WHO guidelines [29]. WC was
measured at the midpoint between the last rib and the
iliac crest [29]. Systolic and diastolic blood pressure were
measured following the JNC-7 guidelines [30].
Abdominal ultrasonography
Abdominal US was performed on fasting subjects by the
same operator using a Logiq 3 Pro instrument equipped
with a 3.5 MHz convex-array probe and with a 7.5 MHz
linear probe (GE Healthcare, Milwaukee, WI, USA).
VAT and SAT were measured 1 cm above the umbilicus.
The examination was performed at end-expiration and
applying the same probe pressure for all subjects. SAT
was measured with the 7.5 MHz linear probe as the dis-
tance between the epidermis and the external face of the
rectus abdominis muscle; VAT was measured with the
3.5 MHz convex-array probe as the distance between
the anterior wall of the aorta and the posterior surface
of the rectus abdominis muscle [14]. Each measurement
was performed 3 times and the mean of the 3 measure-
ments was used for analysis. The within-day intra-
operator coefficient of variation (CV) for repeated mea-
sures of VAT and SAT in our laboratory is 0.8 %.
Laboratory assessment
Fasting blood samples were drawn between 8:30 and
9:00 AM and analyzed in the same morning at the
ICANS laboratory. Glucose, triglycerides, HDL-
cholesterol, alanine transaminase (ALT), gamma-
glutamyl-transferase (GGT) and uric acid were measured
by means of an enzymatic method (Cobas Integra 400
Plus, Roche Diagnostics, Rotkreuz, Switzerland), with
intra-and inter-assay CVs < 2 %. High ALT was defined
as ALT ≥ 30 U/L and high GGT as GGT ≥ 35 U/L [31].
High uric acid was defined as uric acid ≥ 7 mg/dl, i.e.,
the upper normal limit of the ICANS laboratory.
Metabolic syndrome
MS was diagnosed using the harmonized international
definition [32]. In detail, high WC was defined as WC ≥
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102 cm in men and ≥ 88 cm in women; low HDL as
HDL < 40 mg/dl in men and < 50 mg/dl in women; high
triglycerides as triglycerides ≥ 150 mg/dl; high blood
pressure as systolic blood pressure ≥ 130 mmHg or dia-
stolic blood pressure ≥ 85 mmHg or treatment with
pressure-lowering drugs; and high glucose as glucose ≥
100 mg/dl or treatment with glucose-lowering drugs.
Type 2 diabetes mellitus (T2DM) mellitus was defined
as blood glucose ≥ 126 mg/dl or treatment with glucose-
lowering drugs.
Statistical analysis
Most continuous variables were not normally distributed
and all are reported as 50th, 25th and 75th percentiles.
Categorical variables are reported as numbers and per-
centages. All continuous variables besides age were win-
sorized using a tail of 0.01. This implies that values
under the 1st or over the 99th internal percentile were
put equal to the 1st or 99th internal percentile, respect-
ively. Winsorization limits the influence of outliers, a
strategy that is important to increase the generalizability
of regression models [33, 34]. The association of the 4
continuous variables (WC, VAT, SAT, all in cm) or com-
binations of variables (VAT and SAT, all in cm) with the
8 dichotomous outcomes (high triglycerides, low HDL,
high blood pressure, high glucose, MS, high uric acid,
high ALT and high GTT, 0 = no; 1 = yes) was evaluated
using logistic regression models with age (continuous,
years/10) and sex (discrete, 0 = female; 1 =male) as co-
variates [35]. We did not evaluate the association of WC
and MS because WC is included in the definition of MS
[32]. Multivariable fractional polynomials were used to
model non-linear associations of continuous predictors
with the outcomes [36]. Using this approach, we found
that an inverse-transformation of WC (WC−1) and a
loge-transformation of VAT (logevat) ensured linear
logits and better fits for all models. Such transformed
values of WC and VAT were therefore used for the final
analysis. We used the Hosmer-Lemeshow (HL) test and
the standardized Pearson test to assess the goodness of
fit (GOF) of the models [35]. In the few instances where
GOF was rejected by the HL test, it was not rejected by
the more powerful standardized Pearson test. In view of
the available knowledge, we consider this to be a suffi-
cient proof of the acceptable fit of all the models [35].
We used mcfadden pseudo-R2 and the area under the
ROC curve (AUC-ROC) as measures of predictive ability
[35]. To perform a relative comparison of the models we
used the Bayesian information criterion (BIC) [37, 38].
“Weak evidence” in favor of the model with the lower
BIC is said to exist when the BIC difference (ΔBIC) is ≤
2; “positive evidence” when 6 >ΔBIC > 2; “strong evi-
dence” when 6 ≤ ΔBIC < 10; and “very strong evidence”
when ΔBIC > 10 [38, 39]. If ΔBIC < 10, and PSEUDO-R2
and AUC-ROC were not different, we defined the
models similarly associated to the outcome considered.
Results
Table 1 gives the measurements of the 2414 study sub-
jects. They were aged 18 to 66 years and were mostly
women (n = 1714, 71 %).
Table 2 reports the frequency of MS, MS components
(high waist circumference, high triglycerides, low HDL,
high blood pressure and high glucose), high uric acid,
high ALT and high GGT. Table 2 also reports the fre-
quency of subjects treated with glucose-lowering,
triglyceride-lowering, cholesterol-lowering and blood
pressure-lowering drugs. Following current recommenda-
tions [32], subjects taking glucose-lowering drugs were
classified as having high glucose and those taking blood
pressure-lowering drugs as having high blood pressure.
59 % of the subjects had high WC, 19 % high triglycerides,
20 % low HDL, 50 % high blood pressure, 26 % high glu-
cose, 29 % MS, 8 % high uric acid, 25 % high ALT, and
18 % high GGT. Less than 1 % of subjects was taking
glucose-lowering or triglyceride-lowering drugs, 4 %
cholesterol-lowering drugs, and 17 % blood-pressure low-
ering drugs. T2DM was diagnosed in 3 % of subjects.
Table 3 reports the BICs, pseudo-R2 and AUC-ROC
associated with the each of the 31 logistic regression
models. Additional file 1: Table S1 gives the 31 multivar-
iable logistic regression models developed for the ana-
lysis. Among the four parameters of interest, VAT was
independently associated to all outcomes considered. In
addition, logeVAT had the best combination of BIC,
pseudo-R2 and ROC-AUC for high triglycerides (2056,
0.13, 0.75), high ALT (2198, 0.20. 0.80) and high GGT
(1874, 0.18, 0.79). SAT was independently associated to
MS and only with high blood pressure and high ALT
when we considered the single biomarkers of MS and
NAFLD. However, SAT never had the best combination
of BIC, pseudo-R2 and ROC-AUC for anyone of the out-
comes considered when compared to other parameters.
The combination of logeVAT and SAT was associated
with the best combination of BIC, pseudo-R2 and ROC-
AUC for MS (2131, 0.28, 0.84). WC−1 was associated
with the best combination of BIC, pseudo-R2 and ROC-
AUC only for low HDL (2306, 0.06, 0.67) and high blood
pressure (2576, 0.24, 0.81). The combination of pseudo-
R2 and ROC-AUC shows a similar association between
logeVAT and WC
−1 with high glucose and high uric acid.
Only BIC shows a marginal better association of such
outcomes with WC−1.
Discussion
In the present study, we evaluated whether dissecting
abdominal fat in VAT and SAT using US may detect
stronger and more specific association with MS, MS
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components, hyperuricemia and altered liver enzymes
compared to waist circumference. VAT was independ-
ently associated with all the outcomes of interest, while
SAT was independently associated with MS and only
with high blood pressure and high ALT when we consid-
ered the single parameters of MS and NAFLD. VAT had
the strongest association with high triglycerides, high
ALT and high GGT. The VAT + SAT association had the
strongest association with MS. WC had the strongest as-
sociation only with low HDL and high blood pressure.
Lastly, VAT and WC were similarly associated to high
glucose and high uric acid.
High triglycerides
In keeping with the available evidence [2, 6, 22, 24–27],
in the present study, an increasing VAT was associated
with an increasing odds of hypertriglyceridemia. VAT
was more strongly associated with high triglycerides
than were SAT or WC, again in agreement with CT-
based [2] and US-based [26] studies. While some studies
found no association between SAT and hypertriglyc-
eridemia [25, 26], other studies reported a weak associ-
ation [2, 6, 27]. The association that we detected
between SAT and hypertriglyceridemia disappeared after
correction for VAT.
Low HDL
In the present study, VAT and SAT were both associated
with low HDL. However, SAT was associated with low
HDL less strongly than VAT is in agreement with the
previous studies [2, 6, 25–27]. Moreover, after adjust-
ment for VAT, SAT lost its association with low HDL,
suggesting that only VAT increment is involved in the
decrement of serum HDL. Interestingly, contrary to pre-
vious studies [2, 26], we found that WC was more
strongly associated with low HDL than was VAT. This
finding may be partly due to the fact that we studied
subjects at greater risk of CMD.
High blood pressure
A previous association between VAT and hypertension
has been reported by most [2, 6, 20, 25, 26] but not all
[4, 27] studies. The existence of an association between
SAT and hypertension is more controversial. We found a
greater association with high blood pressure for VAT
than for SAT. Interestingly, in agreement with previous
studies [2, 6, 27], VAT and SAT were independently as-
sociated with high blood pressure. In addition, WC was
associated with high blood pressure and more strongly
than was VAT.
High glucose
Consistently with previous studies [2, 6, 25, 26], the as-
sociation of VAT with high glucose was higher than that
of SAT. As reported by most [6, 25, 26] but not all [2]
studies, there was no residual association between SAT
and high glucose after the effect of VAT was controlled
for. Interestingly, in the present study, VAT and WC
Table 1 Measurements of the study subjects
Females (n = 1714) Males (n = 700) Total (n = 2414)
P50 P25 P75 P50 P25 P75 P50 P25 P75
Weight (kg) 72.6 64.2 83.3 92.3 83.5 103.6 78.1 67.4 91.2
Height (m) 1.62 1.57 1.66 1.75 1.71 1.80 1.65 1.59 1.72
BMI (kg/m2) 27.8 24.6 31.9 30.0 27.6 33.4 28.6 25.4 32.4
WC (cm) 90.5 82.0 100.0 105.5 98.0 114.2 95.0 85.1 105.5
VAT (cm) 4.2 3.0 5.8 7.1 5.4 9.0 4.9 3.4 7.1
SAT (cm) 2.8 2.1 3.7 2.7 2.0 3.7 2.8 2.0 3.7
Glucose (mg/dl) 91 85 98 97 91 105 93 87 100
Triglycerides (mg/dl) 82 61 116 121 85 171 91 66 131
Cholesterol (mg/dl) 211 183 239 212 187 240 211 184 240
HDL-cholesterol (mg/dl) 62 53 72 46 39 54 58 47 69
LDL-cholesterol (mg/dl) 128 105 153 138 115 162 130 107 155
ALT (U/l) 17 13 24 31 22 41 20 15 30
GGT (U/l) 16 12 23 31 21 46 19 13 30
Uric acid (mg/dl) 4.3 3.6 5.0 6.2 5.4 6.9 4.7 3.9 5.8
Systolic BP (mm Hg) 120 110 130 130 120 140 120 115 130
Diastolic BP (mm Hg) 75 70 80 80 80 90 80 70 85
BMI Body Mass Index, WC waist circumference, VAT visceral adipose tissue, SAT subcutaneous adipose tissue, ALT alanine transaminase, GGT gamma-glutamyl-transferase,
BP blood pressure
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were similarly associated to high glucose. It should be
noted, indeed, that 1 of the 3 statistical association pa-
rameters considered showed a marginal better associ-
ation of WC with high glucose whereas the others were
superimposable to VAT.
Metabolic syndrome
In the present study, both VAT and SAT were independ-
ently associated with MS. The VAT-MS association is in
line with existing evidences. The contribution of SAT to
MS is, instead, still controversial. Indeed, some [2], but
not all [26], studies report a SAT-MS association. The
contribution of SAT to MS in our subjects is likely to be
due to the independent contribution of SAT to high
blood pressure, which was the second most prevalent
MS component in our subjects (50 %). Interestingly, the
association of VAT and SAT with MS was greater when
they were employed together than when they were used
alone. Other researchers reported that US-determined
VAT was strongly associated with MS in patients at risk
of CMD [26]. However, they found no association of MS
Table 2 Age, nutritional status, components of metabolic
syndrome, high uric acid, high ALT, high GGT in the study
subjects according to sex
Females Males Total
N % N % N %
Age (years)
18–29 204 11.9 67 9.6 271 11.2
30–39 371 21.6 153 21.9 524 21.7
40–49 538 31.4 215 30.7 753 31.2
50–59 392 22.9 153 21.9 545 22.6
60–69 209 12.2 112 16.0 321 13.3
Total 1714 100.0 700 100.0 2414 100.0
Weight status
Normal 476 27.8 57 8.1 533 22.1
Overweight 652 38 286 40.9 938 38.9
Obesity class 1 356 20.8 239 34.1 595 24.6
Obesity class 2 151 8.8 85 12.1 236 9.8
Obesity class 3 79 4.6 33 4.7 112 4.6
Total 1714 100.0 700 100.0 2414 100.0
High waist circumference
No 726 42.4 262 37.4 988 40.9
Yes 988 57.6 438 62.6 1426 59.1
Total 1714 100.0 700 100.0 2414 100.0
High triglycerides
No 1497 87.3 466 66.6 1963 81.3
Yes 217 12.7 234 33.4 451 18.7
Total 1714 100.0 700 100.0 2414 100.0
Low HDL
No 1405 82.0 525 75.0 1930 80.0
Yes 309 18.0 175 25.0 484 20.0
Total 1714 100.0 700 100.0 2414 100.0
High blood pressure
No 1008 58.8 193 27.6 1201 49.8
Yes 706 41.2 507 72.4 1213 50.2
Total 1714 100.0 700 100.0 2414 100.0
High glucose
No 1365 79.6 414 59.1 1779 73.7
Yes 349 20.4 286 40.9 635 26.3
Total 1714 100.0 700 100.0 2414 100.0
Metabolic syndrome
No 1343 78.4 373 53.3 1716 71.1
Yes 371 21.6 327 46.7 698 28.9
Total 1714 100.0 700 100.0 2414 100.0
High uric acid
No 1671 97.5 545 77.9 2216 91.8
Yes 43 2.5 155 22.1 198 8.2
Total 1714 100.0 700 100.0 2414 100.0
Table 2 Age, nutritional status, components of metabolic
syndrome, high uric acid, high ALT, high GGT in the study
subjects according to sex (Continued)
High ALT
No 1475 86.1 341 48.7 1816 75.2
Yes 239 13.9 359 51.3 598 24.8
Total 1714 100.0 700 100.0 2414 100.0
High GGT
No 1552 90.5 434 62.0 1986 82.3
Yes 162 9.5 266 38.0 428 17.7
Total 1714 100.0 700 100.0 2414 100.0
Glucose-lowering drugs
No 1708 99.6 688 98.3 2396 99.3
Yes 6 0.4 12 1.7 18 0.7
Total 1714 100.0 700 100.0 2414 100.0
Triglyceride-lowering drugs
No 1707 99.6 689 98.4 2396 99.3
Yes 7 0.4 11 1.6 18 0.7
Total 1714 100.0 700 100.0 2414 100.0
Cholesterol-lowering drugs
No 1660 96.8 661 94.4 2321 96.1
Yes 54 3.2 39 5.6 93 3.9
Total 1714 100.0 700 100.0 2414 100.0
Blood pressure-lowering drugs
No 1486 86.7 510 72.9 1996 82.7
Yes 228 13.3 190 27.1 418 17.3
Total 1714 100.0 700 100.0 2414 100.0
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with SAT and did not evaluate the joint contribution of
VAT and SAT to MS as we did in the present study [26].
High ALT and high GGT
In a recent study performed in a large sample of subjects
with and without NAFLD, VAT but not SAT was inde-
pendently associated with high ALT [39]. However, the
study did not compare WC and VAT in terms of their
association with high ALT. In another study performed
in overweight Korean women, CT-measured VAT was
the only predictor of serum ALT at multivariable analysis
controlling for SAT and other confounders [40]. A fur-
ther study has confirmed that, after correction for con-
founders, ALT and GGT are higher in patients with
increased VAT [41]. However, the association of WC
with altered liver enzymes was not evaluated. In agree-
ment with such studies, we found that VAT was associ-
ated with both high ALT and high GGT. In addition, we
found that SAT was independently associated only with
high ALT. Interestingly; the present study adds the
information that VAT was associated more strongly than
WC to high ALT and high GGT.
High uric acid
In the present study, VAT and SAT were both associated
with high uric acid. However, the association of SAT
with high uric acid is lost when the effect of VAT is con-
trolled for. An association between CT-measured VAT
and uric acid was recently reported [9]. Such association
persisted after SAT and other confounders were taken into
account. A similar association between CT-measured
VAT and uric acid has been reported among Japanese sub-
jects [42, 43]. In agreement with these studies, the present
study shows that VAT is associated more strongly to hy-
peruricemia than is SAT. Interestingly, VAT and WC were
similarly associated to high uric acid. It should be noted,
indeed, that only one of three statistical parameters con-
sidered in the present study reported a marginal better
association of WC with high uric acid.
Table 3 Association between the four parameters of interest and metabolic syndrome, its components, uric acid and altered liver
enzymes
Model 1 Model 2 Model 3 Model 4
WC logVAT SAT logVAT + SAT
High triglycerides BIC 2085 2056 2175 2063
Pseudo-R2 (McFadden) 0.12 0.13 0.08 0.13
AUC-ROC 0.74 0.75 0.70 0.75
Low HDL BIC 2306 2322 2418 2330
Pseudo-R2 (McFadden) 0.06 0.05 0.01 0.05
AUC-ROC 0.67 0.66 0.58 0.66
High blood pressure BIC 2576 2677 2728 2623
Pseudo-R2 (McFadden) 0.24 0.21 0.19 0.23
AUC-ROC 0.81 0.79 0.78 0.80
High glucose BIC 2327 2330 2463 2334
Pseudo-R2 (McFadden) 0.18 0.18 0.13 0.18
AUC-ROC 0.78 0.78 0.74 0.78
Metabolic syndrome BIC - 2158 2491 2131
Pseudo-R2 (McFadden) - 0.27 0.15 0.28
AUC-ROC - 0.83 0.76 0.84
High uric acid BIC 1113 1117 1154 1125
Pseudo-R2 (McFadden) 0.21 0.21 0.18 0.21
AUC-ROC 0.84 0.84 0.84 0.81
High ALT BIC 2252 2198 2350 2202
Pseudo-R2 (McFadden) 0.18 0.20 0.14 0.20
AUC-ROC 0.78 0.80 0.80 0.75
High GGT BIC 1911 1874 2011 1888
Pseudo-R2 (McFadden) 0.17 0.18 0.12 0.18
AUC-ROC 0.78 0.79 0.74 0.79
Values are Bayesian information criterion (BIC), McFadden pseudo-R2 and areas under the ROC curve (AUC-ROC)
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Study strength and limitations
First strength of our study is its sample size. Second, al-
though the comparison between WC and CT-measured
abdominal fat in relation to the association with meta-
bolic risk factors has been already studied [2], to our
knowledge this is one of the first studies to compare
WC with US measurements of abdominal fat distribu-
tion in relation to their associations with MS and its
components, high uric acid, recently associated to MS
[44–46], and altered hepatic enzymes as biomarkers of
NAFLD. This study has, however, several limitations.
First, we studied a self-selected sample of Caucasian
subjects and our findings cannot be extrapolated to the
general population and to non-Caucasian subjects. On
the other hand, this is the largest study performed so far
that has measured VAT and SAT by US and we believe
that our findings are relevant for researchers interested
into disentangling the effect of US-determined VAT and
SAT on CMD risk. Second, this is a cross-sectional
study. There is a general need of a cohort study aimed at
evaluating the association of VAT and SAT changes with
CMD risk changes. A large cross-sectional study with
carefully standardized measurements of VAT and SAT,
such as the present one, may help to plan such a study.
Third, our outcomes (glucose, triglycerides, cholesterol,
HDL-cholesterol, LDL-cholesterol, alanine transaminase,
gamma-glutamyl-transferase and uric acid) were chosen
because we considered them the most relevant bio-
markers associated to metabolic syndrome and NAFLD.
Never the less, we recognize that it could be interesting
to study the association with some other important risk
factors, such as total and LDL cholesterol, insulin,
hemoglobin glycated and inflammatory parameters in
particular stratifying for obesity degree. Finally, we used
US to quantify abdominal VAT and SAT. Even though
US is not a reference method, it is presently the only
available option to measure abdominal fat in population
studies. On the other hand, our US measurement proto-
col had been thoroughly validated against CT [14, 15]
showing good accuracy and reproducibility and used in
previous epidemiological studies [6, 47, 48]. In addition,
all measurements were performed by the same operator,
reporting a low coefficient of variation.
Conclusion
In conclusion, US-determined VAT and SAT are both in-
dependently associated with MS. VAT is associated to all
of the MS components in addition to hyperuricemia and
altered liver enzymes, and performs equally or better
than WC except for high blood pressure and low HDL.
In contrast, SAT is independently associated only with
high blood pressure and high ALT. These data are of
clinical interest and suggest that the components of ab-
dominal fat, as measured by US, may play at least in part
independent roles in the development of cardiometabolic
risk factors. Cohort studies are needed to test whether
changes in US-measured VATand SATare associated with
changes in the CMD risk profile.
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